Home > Haematology > EHA 2021 > Lymphoma > Promising chemo-free treatment options in r/r DLBCL

Promising chemo-free treatment options in r/r DLBCL

Presented By
Prof. Marco Ladetto, University del Piemonte Orientale, Italy
EHA 2021
Several novel agents and combinations are under development as alternatives to chemotherapy treatment in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). These new agents include novel antibodies, CAR T-cell therapy, checkpoint inhibitors, immunotoxins, PI3K inhibitors, novel kinase inhibitors, BiTE, Bcl-2 inhibitors, and BTK inhibitors [1]. The poor outcomes of chemotherapy in patients with r/r DLBCL create a major unmet medical need for alternative treatment regimes. This is true for patients either eligible or ineligible for transplantation. For example, rituximab + gemcitabine and oxaliplatin (R-GemOx) in r/r DLBCL patients ineligible for autologous transplantation demonstrated a median progression free-survival time of 5 months and a median overall survival of only 10 months [2]. Prof. Marco Ladetto (University del Piemonte Orientale, Italy) discussed the use of non-chemotherapeutic agents in transplant-ineligible r/r DLBCL. N...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on